Robert Motzer, MD
San Francisco—Results from two randomized, Phase III clinical trials presented at the American Society of Clinical Oncology’s Genitourinary Cancers Symposium shed light on the best drug to use for patients with advanced clear cell renal cell carcinoma (RCC) who have progressed on the most common first-line therapy, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI). Both cabozantinib and nivolumab were superior to